Dr. David Aguilar, COO, shared that the company has received pre-launch and pre-orders for our ABBIE technology kits. This is significant miles stone for the company and we are very happy to ...
After giving effect to the Reverse Split of the Company's Common Shares, each 40 Common Shares will be combined into one Common Share, such that the Company's 46,880,000 Common Shares outstanding will ...
2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of their Abecma gene therapy in certain people newly diagnosed with the blood cancer multiple myeloma.